Navigation Links
GeoPharma to Present at EdgeWater Research Partners Conference
Date:4/8/2008

Largo, Fla., April 8, 2008 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) announced that the company will present today at the EdgeWater Research Partners Spring Conference being held at the Grand Hyatt in Denver, Colorado at 2:25 MT.

"We are thoroughly pleased to have GeoPharma present at the spring conference," said EdgeWater President David Lavigne. "GeoPharma has a unique story with a thriving Manufacturing and Distribution business. We expect further positive developments in their Specialty Pharma business with several antibiotic drugs soon to enter into production. Furthermore, the continued development of their Early Stage Ovarian Cancer Diagnostic Device and the value it may add if approved, has not been factored into their current valuation."

EdgeWater Research Partners recently issued a Quarterly update to their Initial Coverage Report on GeoPharma which is currently the featured report on the GeoPharma website. The EdgeWater report and other research reports can be found on the Investor Relations Home Page at http://www.GeoPharmainc.com .

ABOUT EDGEWATER RESEARCH PARTNERS LLC:

EdgeWater Research Partners LLC. is an independent subscription based micro cap stock research company. Subscribers receives a monthly micro cap stock newsletter, in addition to individual company research reports and updates similar to the one's issued on GeoPharma. Annual subscriptions to EdgeWater Research services are available at http://www.edgewaterresearch.com

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the GeoPharma website at http://www.GeoPharmainc.com.

FORWARD-LOOKING STATEMENTS

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoPharma Announces Record Revenues in Third Quarter Results
2. GeoPharma Announces Third Quarter Conference Call
3. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
4. MaxCyte to Present at BIO-Europe Spring 2008 Conference
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Prometic to present at the American Chemical Society
7. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
8. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
11. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it ... biological network, a depiction of a system of linkages and connections so complex ... associate professor of computer science at Worcester Polytechnic Institute (WPI) and director of ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):